Page 145 - Screening for Cervical Cancer: Systematic Evidence Review

Appendix C. Evidence Tables

Evidence Table 3A. Performance of HPV Testing for Screening (cont'd)

Quality
Patients & Methods Outcomes Measured Study Results & Limitations* Considerations
2140 women aged 25 Primary outcome: Prevalence: Quality Score=9
to 55 attending High grade lesions or LGSIL=561/2140=26.2% Ref. Std: 2
primary care clinics cancer (proved by HGSIL=251/2140=10.1% Blind: 2
biopsy and/or Verification: 2
colposcopic Se (High risk HPV, LGSIL+) Consecutive: 0
impression) =64.0% Spectrum: 1
Low grade lesions Sp (High risk HPV, LGSIL+) Publication: 1
(proved by biopsy =64.9% Industry: 1
and/or colposcopic
impression) Se (High risk HPV, HGSIL+) =
80.9%
Secondary outcome: Sp (High risk HPV, HGSIL+) =
Light unit ratios of 61.6%
HPV positive
specimens

1365 previously cytology: Bethesda Prevalence: Quality Score=9
unscreened black system LGSIL=40/1365=2.9% Ref. Std: 2
women aged 35 and HGSIL=47/1365=3.4% Blind: 2
older attending HPV: high risk Ca=9/1365=0.7% Verification: 2
outpatient clinics subtypes (16, 18, 31, Consecutive: 0
33, 35, 45, 51, 52, 56 for clinican-collected specimens: Spectrum: 1
and 58) vs. not Se (High risk HPV, LGSIL+)=81.3% Publication: 1
Sp (High risk HPV, LGSIL+)=84.5% Industry: 1
Colposcopy:
biopsy-confirmed for self-collected specimens:
HGSIL, or cancer Se (High risk HPV, LGSIL+)=
61.5%
Sp (High risk HPV, LGSIL+)=
74.5%

for clinican-collected specimens:
Se (High risk HPV, HGSIL+)=81.3%
Sp (High risk HPV, HGSIL+)=84.5%

for self-collected specimens:
Se (High risk HPV, HGSIL+)=
66.1%
Sp (High risk HPV, HGSIL+)=
82.9%

C-51